The Global Immune Checkpoint Inhibitors Industry 2018 Market Research Report is a professional and in-depth study on the current state of the Immune Checkpoint Inhibitors industry Read More

The global immune checkpoint inhibitors market is expected to witness significant growth as these are proven to be more effective therapy in shrinking tumor in higher proportion of patients… Read More

The immune system of human body depends on multiple checkpoints or immunological breaks, which avoid over-activation of the healthy cells or immune system. Tumor or cancerous cells often tak… Read More

EAGAN, Minn., Feb. 15, 2017 (GLOBE NEWSWIRE) — Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th an… Read More

BOULDER, Colo., Dec. 20, 2017 (GLOBE NEWSWIRE) — Findings published in the American Association for Cancer Research (AACR) peer-reviewed journal Cancer Immunology Research demonstrate… Read More

Dr. Don Benson of The Ohio State University presented in major sessions at ASH 2016 where he described the history and use of checkpoint inhibitors. This article is a summary of this paper… Read More

Dr. Don Benson, MD, PhD Ohio State University Interview Date: June 10, 2016 Summary Ten years ago the first checkpoint inhibitor was used in metastatic melanoma, with amazing results. Now, a… Read More

lksuperboy / Pixabay The News: A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc. (Plymouth Meeting PA) and South Korea’s GeneOne Life Science Inc. induced anti-Zika immune resp… Read More

A new checkpoint inhibitor targeting PD-L1 is now in a myeloma clinical trial to be tested alone, with pomalidomide, or pomalidomide/dexamethasone. Checkpoint inhibitors take the “brak… Read More

A crucial part of treating Cervical Cancer is determining its development stage – early, medial or advanced: Early stage cancers are confined to only the cervix region and can be tre… Read More

geralt / Pixabay The News: Instead of less than 10% of drugs reaching the market, a new study has found that almost 15% of new compounds pass clinical trial–which still suggests that i… Read More

Generally, when the business of a pharmaceutical giant reaches a plateau, its business volume won’t change much during this period. Instead, it will try to optimize its structure, incl… Read More

Story Source David McCarthy/SPL Combining cancer treatments can boost remission rates in patients with kidney cancer. An approach to unleashing immune responses against cancer is showing p… Read More

A new virus has been approved by the Federal Drug Administration (FDA) to treat cancer, especially in patients with stage three melanoma. The new treatment called Imlygic was developed by Am… Read More